Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Thymulin
Also known as: Facteur Thymique Serique, FTS, Serum Thymic Factor
Thymulin is a zinc-dependent nonapeptide hormone produced by thymic epithelial cells. It requires zinc to achieve its biologically active form and plays a key role in T-cell differentiation and immune regulation. Thymulin levels decline with age as the thymus involutes, which has prompted interest in its use as an anti-aging and immune-restoring agent.
Risk Level
Medium RiskDifficulty
Advanced| CAS Number | 63958-90-7 |
| Molecular Formula | C33H54N12O15SZn |
| Class | Peptide |
| Category | Underground Peptides |
Mechanism of Action
Binds to high-affinity receptors on T-cells to promote their differentiation and maturation. Modulates cytokine release, enhances NK cell activity, and influences the hypothalamic-pituitary-adrenal axis. Requires zinc as a cofactor for biological activity.
Dosing Research
No established human dosing protocol exists. Underground use typically involves intranasal or subcutaneous administration at very low doses (micrograms). Often paired with zinc supplementation to ensure bioactivity.
Side Effects & Risks
Very limited human safety data. Theoretical risks include immune dysregulation and autoimmune activation. Zinc dependency means improper formulation may render it inactive rather than harmful.
Research Studies
Related compounds
Semaglutide
PeptideSemaglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic) and chronic weight management (Wegovy). Clinical trials demonstrated average weight loss of 15-17% of body weight. It has become one of the most widely discussed medications in modern weight management.
Tirzepatide
PeptideTirzepatide is a dual GLP-1/GIP receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). It has demonstrated unprecedented weight loss efficacy in clinical trials, with participants losing up to 20-25% of body weight. It represents the cutting edge of pharmaceutical weight management.
Liraglutide
PeptideLiraglutide is a GLP-1 receptor agonist approved for type 2 diabetes (Victoza, 1.8 mg) and obesity (Saxenda, 3.0 mg). It was the first GLP-1 agonist approved specifically for weight management. While effective, it has been largely superseded by semaglutide and tirzepatide in terms of weight loss efficacy.
PT-141
PeptidePT-141 (bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist that was FDA-approved in 2019 as Vyleesi for the treatment of hypoactive sexual desire disorder in premenopausal women. Unlike PDE5 inhibitors, it acts centrally through the melanocortin system to increase sexual desire rather than just facilitating erection mechanics. It is the only FDA-approved on-demand treatment targeting central sexual arousal pathways.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.